ANALYSIS OF HIV PROTECTIVE IMMUNITY

艾滋病疫苗和治疗发展的一个主要障碍是 对什么构成对艾滋病毒的保护性免疫的理解不全面- 1.为了研究体液免疫在预防艾滋病毒感染中的作用，我们 正在研究初代和实验室HIV-1的抗体中和 分离株。我们使用各种新的培养方法来分析这两种 多种多克隆抗体和单抗的敏感性模式 HIV-1的类型。我们发现，中和艾滋病毒的能力 不仅取决于个人的抗体谱系，而且还取决于 患者体内生长的病毒表型。我们发现， 在人群中传播的主要艾滋病毒形式(初级艾滋病毒-1) 逃避免疫，因为它的中和位点是隐蔽的或 隐藏在病毒的膜上。我们的发现具有重要的意义 对艾滋病毒传播和疫苗开发工作的影响。小说 用单抗和类型特异性抗血清进行检测应 提供免疫分型患者分离株的方法和体液的评价 在临床试验中对艾滋病毒候选疫苗的反应。研究是 计划进行异性病毒传播，并开发检测方法 测量阴道产品中使用的抗病毒化合物。

A major obstacle to AIDS vaccine and therapeutic development is the incomplete understanding of what constitutes protective immunity to HIV- 1. To study the role of humoral immunity in preventing HIV infection, we are investigating antibody neutralization of primary and laboratory HIV-1 isolates. Using a variety of novel culture methods we are anlyzing both polyclonal and monoclonal antibodies sensitivity patterns of a variety of HIV-1 types. We are finding that the ability to neutralize HIV depends not only on the antibody repertoire of an individual but also on the virus phenotype growing in the patient. We have discovered that the predominant form of HIV transmitted in the population (primary HIV-1) escapes from immunity because its neutralizing sites are cryptic or hidden on the membrane form of the virus. Our findings have important implications for HIV transmission and vaccine development efforts. Novel assays with monoclonal antibodies and type specific antisera should provide methods to immunotype patient isolates and to evaluate humoral responses to HIV vaccine candidates in clinical trials. Studies are planned on heterosexual virus transmission and on developing assays to measure antiviral compounds used in vaginal products.